| Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma MJ Borad, MD Champion, JB Egan, WS Liang, R Fonseca, AH Bryce, ... PLoS genetics 10 (2), e1004135, 2014 | 356 | 2014 |
| Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, ... JAMA oncology 3 (12), e173290-e173290, 2017 | 279 | 2017 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 196 | 2019 |
| Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer E Galanis, PJ Atherton, MJ Maurer, KL Knutson, SC Dowdy, WA Cliby, ... Cancer research 75 (1), 22-30, 2015 | 194 | 2015 |
| Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes A Kotwal, C Haddox, M Block, YC Kudva BMJ Open Diabetes Research and Care 7 (1), e000591, 2019 | 184 | 2019 |
| Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer H Shen, BL Fridley, H Song, K Lawrenson, JM Cunningham, SJ Ramus, ... Nature communications 4 (1), 1628, 2013 | 178 | 2013 |
| IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer P Lamichhane, L Karyampudi, B Shreeder, J Krempski, D Bahr, J Daum, ... Cancer research 77 (23), 6667-6678, 2017 | 147 | 2017 |
| The use of pembrolizumab for the treatment of metastatic uveal melanoma LA Kottschade, RR McWilliams, SN Markovic, MS Block, JV Bisneto, ... Melanoma research 26 (3), 300-303, 2016 | 105 | 2016 |
| Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel MS Cicek, DC Koestler, BL Fridley, KR Kalli, SM Armasu, MC Larson, ... Human molecular genetics 22 (15), 3038-3047, 2013 | 101 | 2013 |
| First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1 N Somaiah, MS Block, JW Kim, GI Shapiro, KT Do, P Hwu, JP Eder, ... Clinical Cancer Research 25 (19), 5808-5817, 2019 | 78 | 2019 |
| Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients KR Kalli, MS Block, PM Kasi, CL Erskine, TJ Hobday, A Dietz, D Padley, ... Clinical Cancer Research 24 (13), 3014-3025, 2018 | 77 | 2018 |
| T cell Bim levels reflect responses to anti–PD-1 cancer therapy RS Dronca, X Liu, SM Harrington, L Chen, S Cao, LA Kottschade, ... JCI insight 1 (6), 2016 | 76 | 2016 |
| PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples B Winterhoff, L Freyer, E Hammond, S Giri, S Mondal, D Roy, A Teoman, ... European Journal of Cancer 51 (7), 879-892, 2015 | 63 | 2015 |
| Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10 B Charbonneau, MS Block, WR Bamlet, RA Vierkant, KR Kalli, Z Fogarty, ... Cancer research 74 (3), 852-861, 2014 | 61 | 2014 |
| The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins Z Li, MS Block, RA Vierkant, ZC Fogarty, SJ Winham, DW Visscher, ... Tumor Biology 37, 13279-13286, 2016 | 60 | 2016 |
| Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients MS Block, AB Dietz, MP Gustafson, KR Kalli, CL Erskine, B Youssef, ... Nature communications 11 (1), 5173, 2020 | 58 | 2020 |
| Plasma immune analytes in patients with epithelial ovarian cancer MS Block, MJ Maurer, K Goergen, KR Kalli, CL Erskine, MD Behrens, ... Cytokine 73 (1), 108-113, 2015 | 46 | 2015 |
| Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers G Colon-Otero, V Zanfagnin, X Hou, NR Foster, EJ Asmus, ... ESMO open 5 (5), e000926, 2020 | 44 | 2020 |
| Inflammatory and nutritional serum markers as predictors of peri-operative morbidity and survival in ovarian cancer A Kumar, ML Torres, WA Cliby, KR Kalli, G Bogani, G Aletti, ... Anticancer research 37 (7), 3673-3677, 2017 | 44 | 2017 |
| Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers G Colon-Otero, SJ Weroha, NR Foster, P Haluska, X Hou, ... Gynecologic oncology 146 (1), 64-68, 2017 | 44 | 2017 |
